Finch Therapeutics works on microbiome therapies including CP101 for C. diff using spore-based approaches. It maintains a pipeline of investigational treatments and some data-sharing initiatives. Compared with OpenBiome it focuses more on proprietary development than open foundation resources and has faced typical biotech funding and regulatory timelines.
Free